Study to evaluate the the effect of natalizumab discontinuation on cognitive functions in patients with relapsing remitting multiple sclerosis.

Trial Profile

Study to evaluate the the effect of natalizumab discontinuation on cognitive functions in patients with relapsing remitting multiple sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2015 New trial record
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top